Zhejiang University School of Medicine, Hangzhou, 310006, China.
Department of Oncology, Hangzhou First People's Hospital, Hangzhou, 310006, China.
Biomark Med. 2024;18(15-16):703-715. doi: 10.1080/17520363.2024.2385297. Epub 2024 Aug 15.
Biliary tract cancers (BTCs) have rising incidence and mortality rates. Chemotherapy's limited efficacy has led to exploring new treatments like immunotherapy. which offers modest benefits. Moreover, the identification of reliable predictive biomarkers for immune checkpoint therapy in BTCs remains elusive, hindering personalized treatment strategies. This review provides an overview of the current landscape of emerging biomarkers for immunotherapy response in BTCs. We discuss the incremental benefits of combination therapy and the evolving role of immunotherapy in managing advanced BTC. Additionally, we highlight the need for robust predictive biomarkers to optimize treatment outcomes and foster a more individualized approach to patient care. We aim to identify promising research avenues and strategies to enhance therapeutic efficacy and patient survival in BTCs.
胆道癌（BTCs）的发病率和死亡率呈上升趋势。化疗的疗效有限，促使人们探索新的治疗方法，如免疫疗法，其带来的获益有限。此外，BTC 中免疫检查点治疗可靠的预测生物标志物仍难以确定，阻碍了个体化治疗策略的制定。本综述概述了 BTC 免疫治疗反应中新兴生物标志物的研究现状。我们讨论了联合治疗的附加获益，以及免疫治疗在管理晚期 BTC 中的作用不断演变。此外，我们强调需要稳健的预测生物标志物，以优化治疗效果，促进患者个体化治疗。我们旨在确定有前途的研究途径和策略，以提高 BTC 的治疗效果和患者生存率。
